As expected the strongest associations were obtained for SNPs mapping to 15q25.1 (rs8034191, OR = 1.29, 95% CI: 1.23–1.35; P = 3.24 × 10−26), 5p15.33 (rs4975616, OR = 0.87, 95% CI: 0.83–0.91; P = 2.99 × 10−9), and 6p21.33 (rs3117582, OR = 1.24, 95% CI: 1.16–1.33; P = 4.46 × 10−10) (Supplementary Table 4). In the meta-analysis the strongest association at 15q25.1 was for rs8034191 which lies 80kb outside of CHRNA3. This SNP is in strong LD with rs12914385 (r2 = 0.72 based on HapMap CEU; r2 = 0.73 based on UK-GWA Phase 2 controls). Excluding SNPs mapping to 15q25.1, 5p15.33, 6p21.33, seven SNPs were associated with lung cancer risk at P < 10−5 (Supplementary Table 5). The most significant association is provided by rs748404 (OR = 0.87, 95% CI: 0.83–0.92; P = 1.08 × 10−6), mapping to 41,346,523bp on 15q15.2. Two other SNPs associated with lung cancer risk at P < 10−5 also map to 15q15.2 (rs504417 and rs11853991, 41,341,518bp and 41,344,841bp respectively) and are in strong LD with rs748404 (respective r2 values for: rs748404–rs504417, rs748404–rs504417 are 0.65 and
